Tempus AI (NASDAQ:TEM) CAO Sells $529,650.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan Bartolucci sold 7,062 shares of the stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $75.00, for a total transaction of $529,650.00. Following the transaction, the chief accounting officer directly owned 60,804 shares in the company, valued at approximately $4,560,300. This represents a 10.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Trading Down 3.1%

NASDAQ:TEM traded down $2.52 during trading hours on Friday, reaching $77.84. The company’s stock had a trading volume of 9,310,212 shares, compared to its average volume of 7,226,184. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. The firm has a market capitalization of $14.04 billion, a price-to-earnings ratio of -54.06 and a beta of 3.72. The firm has a 50-day simple moving average of $57.19 and a 200-day simple moving average of $52.90. Tempus AI, Inc. has a 1 year low of $40.77 and a 1 year high of $104.32.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. The business had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company’s revenue was up 21.6% on a year-over-year basis. During the same period in the prior year, the business posted ($0.22) earnings per share. Research analysts expect that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: CEO commentary outlining Tempus AI’s growth strategy and projected Medicare revenue has strengthened confidence that reimbursement expansion could provide a significant new revenue stream. Tempus AI Stock Roars Back 92% From July Low After CEO Lays Out Growth Plan
• Positive Sentiment: Morgan Stanley’s updated outlook reportedly incorporated additional reimbursement-driven revenue potential, helping fuel a sharp weekly advance in TEM shares and reinforcing the bullish growth narrative. Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook
• Positive Sentiment: Trading momentum remains strong: shares have rebounded roughly 92% to 95% from the July low, with market capitalization moving above $14 billion. Above-average volume and elevated call-option activity indicate substantial speculative interest. Tempus AI Stock Is Soaring
• Neutral Sentiment: Analysts and market commentators are assessing whether the recent surge can continue. The rally has improved sentiment, but the sharp move also raises the risk of profit-taking and increased volatility. Strength Seen in Tempus
• Negative Sentiment: Zacks cautioned that recent earnings-estimate revision trends may not support another near-term advance, while brokerages maintain an average “Hold” rating. Tempus also remains unprofitable, making the stock particularly sensitive to valuation concerns and changes in growth expectations. Tempus AI Receives Average Hold Rating

Institutional Trading of Tempus AI

Several institutional investors and hedge funds have recently bought and sold shares of the stock. EMC Capital Management bought a new stake in shares of Tempus AI in the 2nd quarter worth approximately $29,000. Whittier Trust Co. increased its position in Tempus AI by 190.0% during the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after buying an additional 570 shares in the last quarter. Global Assets Advisory LLC bought a new position in Tempus AI during the 1st quarter valued at approximately $46,000. CoreCap Advisors LLC raised its stake in Tempus AI by 293.4% during the second quarter. CoreCap Advisors LLC now owns 1,019 shares of the company’s stock valued at $59,000 after buying an additional 760 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. purchased a new position in Tempus AI during the fourth quarter valued at $70,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on TEM shares. UBS Group assumed coverage on shares of Tempus AI in a research note on Wednesday, September 9th. They set a “neutral” rating and a $70.00 price objective for the company. Guggenheim upped their price target on Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. TD Cowen reiterated a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Piper Sandler raised Tempus AI from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $56.00 to $76.00 in a research note on Tuesday, September 1st. Finally, Weiss Ratings raised Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, September 11th. Eleven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Tempus AI has an average rating of “Hold” and an average target price of $69.33.

About Tempus AI

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.